抗人CXCL10/IP-10/CRG-2参考抗体)

Anti-Human CXCL10/IP-10/CRG-2 Reference Antibody

货号：RB9T37014552

在您使用本产品前请认真阅读说明书，这对您顺利完成实验很有帮助。

产品编码
RB9T37014552

中文名称
抗人CXCL10/IP-10/CRG-2参考抗体)

英文名称
Anti-Human CXCL10/IP-10/CRG-2 Reference Antibody

形态
Liquid

纯度
>95% as determined by SDS-PAGE.

内毒素水平
Please contact with the lab for this information.

应用
ELISA, Bioactivity: FACS, Functional assay, Research in vivo

种属
Human

表达系统
Mammalian Cells

登录号
P02778

宿主种属
Human

克隆性
Monoclonal

抗体亚型
IgG1-kappa

纯化方式
Protein A/G purified from cell culture supernatant.

浓度
1 mg/ml

种属反应性

Human

靶标

Gamma-IP10, C-X-C motif chemokine 10, INP10, 10 kDa interferon gamma-induced protein, Small-inducible cytokine B10, SCYB10, IP-10, CXCL10

背景信息

Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (CXC motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10). This drug was developed by Bristol-Myers Squibb and Medarex and designed for the treatment of Crohn's disease and ulcerative colitis. To date, eldelumab has been investigated as an induction and maintenance therapy in active Crohn's disease, and its induction treatment demonstrated trends towards clinical and endoscopic efficacy with no new safety signal in a phase IIa study. Meanwhile, inhibiting IP-10 activity through the use of the monoclonal antibody, eldelumab, demonstrated efficacy in patients who achieved high serum concentrations in this phase II, randomized, controlled, proof-of-concept study of moderate-to-severe ulcerative colitis.

• The human gene encoding SCYB9B, a putative novel CXC chemokine, maps to human chromosome 4q21 like the closely related genes for MIG (SCYB9) and INP10 (SCYB10)., PMID:9730616

别名

BMS-936557, MDX-1100, 946414-98-8

储存缓冲液

0.01M PBS, pH 7.4.

稳定性和储存

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4° C short term (1-2 weeks). Store at -20° C 12 months. Store at -80° C long term.

For research use only. Not suitable for clinical or therapeutic use.